Back to top
more

NovoCure Limited (NVCR)

(Real Time Quote from BATS)

$17.97 USD

17.97
942,871

+0.07 (0.39%)

Updated Aug 19, 2024 03:43 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Earnings Season Could Be Great for NovoCure (NVCR)

by Zacks Equity Research

NovoCure (NVCR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

NovoCure (NVCR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

NovoCure (NVCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are Options Traders Betting on a Big Move in NovoCure (NVCR) Stock?

by Zacks Equity Research

Investors need to pay close attention to NovoCure (NVCR) stock based on the movements in the options market lately.

    Healthcare Stock Q3 Earnings Due on Oct 29: NVCR, CRL & More

    by Zacks Equity Research

    Coronavirus is going to affect the earnings results of healthcare players. While hospitals and health insurers might have suffered the COVID-19 impact, others providing virtual care and COVID-19-related services are likely to have gained from the same.

    Kroger, Hyatt Hotels, ResMed, LHC Group and NovoCure highlighted as Zacks Bull and Bear of the Day

    by Zacks Equity Research

    Kroger, Hyatt Hotels, ResMed, LHC Group and NovoCure highlighted as Zacks Bull and Bear of the Day

    Sriparna Ghosal headshot

    3 Large-Cap MedTech Growth Stocks to Buy Amid the Pandemic

    by Sriparna Ghosal

    Let's take a look at three large-cap MedTech stocks that are currently flourishing on the back of a number of positive developments.

    Jabil, Harley-Davidson, TMO, LHCG and NovoCure as Zacks Bull and Bear of the Day

    by Zacks Equity Research

    Jabil, Harley-Davidson, TMO, LHCG and NovoCure as Zacks Bull and Bear of the Day

    Debanjana Dey headshot

    3 Growth-Focused MedTech Stocks to Buy Amid the COVID-19 Crisis

    by Debanjana Dey

    Here are three growth stocks from the MedTech space which have maintained stellar performance even during the pandemic-led market meltdown.

    Is NovoCure (NVCR) Outperforming Other Medical Stocks This Year?

    by Zacks Equity Research

    Is (NVCR) Outperforming Other Medical Stocks This Year?

    NovoCure (NVCR) Q2 Earnings Preview: What's in the Cards?

    by Zacks Equity Research

    NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    NovoCure (NVCR) Lags Q1 Earnings and Revenue Estimates

    by Zacks Equity Research

    NovoCure (NVCR) delivered earnings and revenue surprises of -20.00% and -2.19%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

    NovoCure (NVCR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

    by Zacks Equity Research

    NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Urmimala Biswas headshot

    Medical Services Outlook Bright Amid Coronavirus Crisis

    by Urmimala Biswas

    Despite the coronavirus-led worldwide sales disruption, medical services is one of the few sectors witnessing industry-wide growth right now.

    NovoCure (NVCR) Q4 Earnings and Revenues Beat Estimates

    by Zacks Equity Research

    NovoCure (NVCR) delivered earnings and revenue surprises of 300.00% and 0.11%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

    Benjamin Rains headshot

    Expand Your Portfolio with this First Profit Stock Screener

    by Benjamin Rains

    We are in the midst of the fourth quarter earnings season. This makes it a great time to use our 'First Profit' stock screener. The idea is to search for companies that recently reported their first quarterly profit...

    NovoCure (NVCR) Q3 Earnings and Revenues Beat Estimates

    by Zacks Equity Research

    NovoCure (NVCR) delivered earnings and revenue surprises of 140.00% and 4.82%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

    Will NovoCure (NVCR) Report Negative Earnings Next Week? What You Should Know

    by Zacks Equity Research

    NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?

    by Zacks Equity Research

    Style Box ETF report for FNY

    Sweta Killa headshot

    Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?

    by Sweta Killa

    Style Box ETF report for FNY

    Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?

    by Zacks Equity Research

    Style Box ETF report for FNY

    NovoCure Limited (NVCR) Shares March Higher, Can It Continue?

    by Zacks Equity Research

    As of late, it has definitely been a great time to be an investor in NovoCure Limited (NVCR).

    NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    NovoCure (NVCR) delivered earnings and revenue surprises of 85.71% and 6.38%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

    Can NovoCure's (NVCR) Steady Optune Business Aid Q2 Earnings?

    by Zacks Equity Research

    NovoCure (NVCR) expects to deliver a strong second quarter on solid performance by Optune business.

    NovoCure (NVCR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

    by Zacks Equity Research

    NovoCure (NVCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    NovoCure (NVCR) Jumps: Stock Rises 7.1%

    by Zacks Equity Research

    NovoCure (NVCR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.